Disulfidptosis contributes to rotenone-induced dopaminergic neuron damage.
Abstract
Parkinson's disease is a neurodegenerative disorder whose pathogenesis remains incompletely understood. Rotenone exposure is reportedly associated with Parkinson's disease. In addition, disulfidptosis is a newly identified form of cell death. Interestingly, an analysis of the Gene Expression Omnibus Parkinson's disease database indicated that approximately 30 genes that are significantly altered in patients with Parkinson's disease are associated with disulfidptosis. In the present study, using proteomics, a number of important proteins related to disulfidptosis were identified as significantly altered in rotenone-exposed dopaminergic neurons. Further analysis revealed that the formation of abnormal disulfide bonds was also increased in rotenone-exposed dopaminergic neurons. The protein expression of solute carrier family 7 member 11 and amino acid transporter heavy chain SLC3A2 was upregulated in rotenone-exposed dopaminergic neurons, and was correlated with extracellular matrix protein 1 protein expression. These findings indicate that in rotenone-exposed PC12 cells, a cystine influx is triggered, and the conversion of cystine to cysteine is inhibited by a reduction in the oxidized nicotinamide adenine dinucleotide phosphate/reduced nicotinamide adenine dinucleotide phosphate ratio, which leads to cystine accumulation. This excessive accumulation of cystine then promotes the formation of abnormal disulfide bonds in cells, ultimately resulting in disulfidptosis of rotenone-exposed dopaminergic neurons. In this process, the Rasrelated C3 botulinum toxin substrate 1/WAVE regulatory complex/actin-related protein 2/3 pathway was markedly activated, which led to the collapse of the cytoskeleton in rotenone-exposed PC12 cells. Together, our findings suggest that rotenone may induce solute carrier family 7 member 11 expression through extracellular matrix protein 1 activation to cause cystine accumulation, which results in disulfidptosis characterized by cytoskeleton collapse. The present results provide new perspectives for research into neurodegenerative diseases.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 | |
| 해부 | rotenone-exposed
|
scispacy | 1 | ||
| 해부 | extracellular matrix protein 1
|
scispacy | 1 | ||
| 해부 | rotenone-exposed PC12 cells
|
scispacy | 1 | ||
| 해부 | cells
|
scispacy | 1 | ||
| 해부 | cytoskeleton
|
scispacy | 1 | ||
| 해부 | Parkinson's
|
scispacy | 1 | ||
| 해부 | cell
|
scispacy | 1 | ||
| 해부 | rotenone-exposed dopaminergic neurons
|
scispacy | 1 | ||
| 약물 | solute
|
scispacy | 1 | ||
| 약물 | Rotenone
|
C0035871
rotenone
|
scispacy | 1 | |
| 약물 | disulfide
|
C0012771
Disulfides
|
scispacy | 1 | |
| 약물 | amino acid
|
C0002520
Amino Acids
|
scispacy | 1 | |
| 약물 | cystine
|
C0010682
cystine
|
scispacy | 1 | |
| 약물 | cysteine
|
C0010654
cysteine
|
scispacy | 1 | |
| 약물 | nicotinamide adenine
|
scispacy | 1 | ||
| 질환 | Disulfidptosis
|
scispacy | 1 | ||
| 질환 | Parkinson's disease
|
C0030567
Parkinson Disease
|
scispacy | 1 | |
| 질환 | neurodegenerative disorder
|
C0524851
Neurodegenerative Disorders
|
scispacy | 1 | |
| 질환 | death
|
C0011065
Cessation of life
|
scispacy | 1 | |
| 질환 | Parkinson's disease database indicated that approximately 30 genes that are significantly altered
|
scispacy | 1 | ||
| 질환 | disease
|
scispacy | 1 | ||
| 기타 | amino acid transporter heavy chain
|
scispacy | 1 | ||
| 기타 | SLC3A2
|
scispacy | 1 | ||
| 기타 | cysteine
|
scispacy | 1 | ||
| 기타 | Omnibus Parkinson
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 |
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.